{
    "clinical_study": {
        "@rank": "77387", 
        "arm_group": [
            {
                "arm_group_label": "unilateral metal stent insertion", 
                "arm_group_type": "Active Comparator", 
                "description": "unilateral metal stent insertion was performed either left or right hepatic lobe as can be drainage more  liver volume"
            }, 
            {
                "arm_group_label": "bilateral metal stent insertion", 
                "arm_group_type": "Experimental", 
                "description": "percutaneous transhepatic biliary drainage  plus bilateral metal stent.The bare stents were used for PTBS"
            }
        ], 
        "brief_summary": {
            "textblock": "Cholangiocarcinoma (CCA) is the most common biliary malignancy and the second most common\n      hepatic malignancy after hepatocellular carcinoma (HCC). A majority of the CCA (50-70%) was\n      presented in the area of the biliary duct bifurcation. Recent retrospective study included\n      heterogeneous group of malignant diseases demonstrate that draining more than 50% of was\n      associated with a longer median survival.\n\n      However, in recent European Society of Gastrointestinal Endoscopy (ESGE) biliary stenting\n      clinical guideline and Asia-Pacific consensus recommendations for endoscopic and\n      interventional management of hilar cholangiocarcinoma (HCCA), whether we should deployment\n      bilateral or unilateral metal stent for patients with HCCA was not clearly recommended due\n      to the absence of randomized controlled trials."
        }, 
        "brief_title": "Percutaneous Bilateral Versus Unilateral Metal Stent for Hilar Cholangiocarcinoma", 
        "completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Hilar Cholangiocarcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Cholangiocarcinoma", 
                "Klatskin's Tumor"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients with advanced hilar obstruction (Bismuth III and IV), PTBS had a higher success\n      rate of cholestasis palliation and a low rate of post cholangitis when compared with\n      endoscopic retrograde cholangiopancreatography(ERCP). The advantage of percutaneous approach\n      is the precise lobar selection for drainage and this approach should yield a lower rate of\n      cholangitis.\n\n      Guideline recommendation European Society of Gastrointestinal Endoscopy (ESGE) biliary\n      stenting clinical guideline and Asia-Pacific consensus recommendations the goal of\n      palliative stenting of HCCA is drainage of adequate liver volume (50% or more), irrespective\n      of unilateral, bilateral, or multi-segmental stenting was based on heterogeneous group of\n      malignancy by ERCP in retrospective study.There are no randomized clinical trials compared\n      with these two internal biliary drainage methods in HCCA using metal stent.\n\n      The aim of the present study was to compare the effect and safety of bilateral versus\n      unilateral stenting in patients with HCCA."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Written informed consent;Jaundice duo to biliary obstruction;The diagnosis is based on\n        typical features on MRI and magnetic resonance cholangiopancreatography  or histologic and\n        cytologic confirmation is established by percutaneous biopsy (X ray-guided) or exploratory\n        laparotomy;Bismuth type \u2161\u3001\u2162\u3001\u2163obstruction; Performance status (eastern cooperative oncology\n        group, ECOG) 0-2; All patients were considered unsuitable or refuse for resection on the\n        basis of general medical condition and/or tumor extent.\n\n        Exclusion Criteria:\n\n        Refuse to participate and provide informed consent ; Bismuth \u2160 type  obstruction;\n        Performance status (eastern cooperative oncology group, ECOG) 3-4. Portal Vein\n        involvement; Prior history of stent; Concomitant renal insufficiency; Severe\n        cardiopulmonary diseases; Uncontrolled systemic infection or sepsis; Accompany other\n        malignancy or serious medical illness which may reduce the life expectancy.\n\n        Contraindications for PTBS."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "254", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 31, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02108145", 
            "org_study_id": "XHDD-004"
        }, 
        "intervention": [
            {
                "arm_group_label": "bilateral metal stent insertion", 
                "intervention_name": "bilateral metal stent insertion", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "unilateral metal stent insertion", 
                "intervention_name": "unilateral metal stent insertion", 
                "intervention_type": "Procedure"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "cholangiocarcinoma", 
            "jaundice", 
            "metal stent", 
            "PTBS"
        ], 
        "lastchanged_date": "April 8, 2014", 
        "number_of_arms": "2", 
        "official_title": "Percutaneous Bilateral Versus Unilateral Metal Stent Placement for Hilar Cholangiocarcinoma : A Prospective Open-label Randomized Controlled Trial", 
        "other_outcome": [
            {
                "description": "Stent patency is a secondary endpoint of this study. Cumulative stent patency rate is compared between the two groups.", 
                "measure": "Stent patency", 
                "safety_issue": "No", 
                "time_frame": "up to 1year"
            }, 
            {
                "description": "Early major complications is a secondary endpoint of this study.Early major complications rate is compared between the two groups", 
                "measure": "Early major complications", 
                "safety_issue": "Yes", 
                "time_frame": "30 days within treatment"
            }, 
            {
                "description": "30-day mortality is a secondary endpoint of this study. 30-day mortality rate is compared between the two groups.", 
                "measure": "30-day mortality", 
                "safety_issue": "Yes", 
                "time_frame": "30 days within treatment"
            }
        ], 
        "overall_contact": {
            "email": "hangh@fmmu.edu.cn", 
            "last_name": "Guohong Han, MD,Ph.D", 
            "phone": "86-29-84771528"
        }, 
        "overall_contact_backup": {
            "email": "lmw_jack@china.com.cn", 
            "last_name": "MingWu Li, MD"
        }, 
        "overall_official": {
            "affiliation": "Fourth Military Medical University", 
            "last_name": "Guohong Han, MD,Ph.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Successful drainage is a primary endpoint of this study. Successful drainage rate is compared between the two groups.", 
            "measure": "Successful drainage", 
            "safety_issue": "No", 
            "time_frame": "From stent insertion to two weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02108145"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fourth Military Medical University", 
            "investigator_full_name": "Guohong Han", 
            "investigator_title": "Head of Department of Digestive Interventional Radiology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Median survival", 
            "safety_issue": "No", 
            "time_frame": "up to 1 year"
        }, 
        "source": "Fourth Military Medical University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fourth Military Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}